Novavax Inc. (Nasdaq: NVAX) will begin a Phase 1 Ebola vaccine clinical trial in December. Shares of the biopharmaceutical climbed 67 cents to close at $5.80.
Novavax to begin Ebola vaccine trials
October 27, 2014 at 17:34 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.